COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines' Side Effects.
COVID-19
cohort studies
cross-sectional studies
drug-related side effects and adverse reactions
health personnel
mass vaccination
prevalence
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
25 07 2021
25 07 2021
Historique:
received:
27
05
2021
revised:
19
07
2021
accepted:
20
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
12
8
2021
Statut:
epublish
Résumé
Coronavirus disease (COVID-19) vaccine-related side effects have a determinant role in the public decision regarding vaccination. Therefore, this study has been designed to actively monitor the safety and effectiveness of COVID-19 vaccines globally. A multi-country, three-phase study including a cross-sectional survey to test for the short-term side effects of COVID-19 vaccines among target population groups. In the second phase, we will monitor the booster doses' side effects, while in the third phase, the long-term safety and effectiveness will be investigated. A validated, self-administered questionnaire will be used to collect data from the target population; Results: The study protocol has been registered at ClinicalTrials.gov, with the identifier NCT04834869. CoVaST is the first independent study aiming to monitor the side effects of COVID-19 vaccines following booster doses, and the long-term safety and effectiveness of said vaccines.
Sections du résumé
BACKGROUND
Coronavirus disease (COVID-19) vaccine-related side effects have a determinant role in the public decision regarding vaccination. Therefore, this study has been designed to actively monitor the safety and effectiveness of COVID-19 vaccines globally.
METHODS
A multi-country, three-phase study including a cross-sectional survey to test for the short-term side effects of COVID-19 vaccines among target population groups. In the second phase, we will monitor the booster doses' side effects, while in the third phase, the long-term safety and effectiveness will be investigated. A validated, self-administered questionnaire will be used to collect data from the target population; Results: The study protocol has been registered at ClinicalTrials.gov, with the identifier NCT04834869.
CONCLUSIONS
CoVaST is the first independent study aiming to monitor the side effects of COVID-19 vaccines following booster doses, and the long-term safety and effectiveness of said vaccines.
Identifiants
pubmed: 34360156
pii: ijerph18157859
doi: 10.3390/ijerph18157859
pmc: PMC8345554
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT04834869']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Masaryk University
ID : MUNI/IGA/1543/2020
Organisme : Masaryk University
ID : MUNI/A/1608/2020
Références
J Med Virol. 2021 Jul;93(7):4420-4429
pubmed: 33822361
Ann Intern Med. 2020 Dec 15;173(12):964-973
pubmed: 32886525
Vaccine. 2019 Apr 24;37(18):2494-2501
pubmed: 30940484
Vaccine. 2015 Aug 14;33(34):4180-90
pubmed: 25896377
Drug Saf. 2014 Aug;37(8):581-96
pubmed: 25022829
Vaccine. 2015 Aug 14;33(34):4176-9
pubmed: 25896376
BMJ. 2021 Mar 19;372:n774
pubmed: 33741638
Lancet. 1995 Mar 4;345(8949):567-9
pubmed: 7619183
Int J Gen Med. 2021 Apr 19;14:1389-1401
pubmed: 33907443
Data Brief. 2021 Jun;36:107098
pubmed: 33969163
Vaccines (Basel). 2021 Feb 19;9(2):
pubmed: 33669659
Medicina (B Aires). 2021;81(3):408-414
pubmed: 34137701
Public Health. 2020 Mar;180:38-45
pubmed: 31838344
J Clin Med. 2021 Jun 15;10(12):
pubmed: 34203769
Eur J Epidemiol. 2020 Aug;35(8):775-779
pubmed: 32785815
Eur J Epidemiol. 2020 Apr;35(4):325-330
pubmed: 32318915
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
J Clin Med. 2021 Apr 01;10(7):
pubmed: 33916020
J Clin Med. 2021 Jan 14;10(2):
pubmed: 33466777
PLoS Curr. 2017 Mar 3;9:
pubmed: 28357154
Life (Basel). 2021 Mar 17;11(3):
pubmed: 33803014